Cerebrotendinous Xanthomatosis (CTX)

0
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Travere Therapeutics
1 program
Cerebrotendinous Xanthomatosis (CTX) Prevalence StudyN/A1 trial
Active Trials
NCT02638220Completed442Est. Feb 2021

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Travere TherapeuticsCerebrotendinous Xanthomatosis (CTX) Prevalence Study

Clinical Trials (1)

Total enrollment: 442 patients across 1 trials

NCT02638220Travere TherapeuticsCerebrotendinous Xanthomatosis (CTX) Prevalence Study

Cerebrotendinous Xanthomatosis (CTX) Prevalence Study

Start: Sep 2015Est. completion: Feb 2021442 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 companies competing in this space